PP Defence TherapeuticsNews - Page 1

Defence Therapeutics advances radio-immuno-conjugates with CNRI-H Program approval

Defence Therapeutics Inc. has announced a significant milestone in its radio-immuno-conjugates project. The Canadian Nuclear Research Initiative Health (CNRI-H) Program application by Defence Therapeutics has been approved by...

Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)

Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with...

Defence Therapeutics’ ARM-X vaccine completely inhibits ovarian cancer growth in treated animals

Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer...

Innovation News Network - Free Digital eBook Library

Innovation News Network - Global Innovation Partners

Special Reports

Partner News

Special Reports Cont'd

Partner News Cont'd